Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | CSO & EVP Clinical Development | February 01, 2024 | February 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emmaus Life Sciences, Inc.
Report date February 01, 2024 · Filed February 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2034-01-31 | Direct | 200,000 |
Reported balance
After 2024-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 200,000 · Balance 200,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2024 Filed Feb 5, 2024 21:37 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | GrantOptions · Derivative | 200,000 | $0.15 Strike: $0.15 | $30,000.00 |
DisclosureSEC source: 0001209191-24-002804 · doc4.xml · derivative · entry 1 Stark Charles William · CIK 0001901666 · CSO & EVP Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-31 Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 19:32 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | GrantOptions · Derivative | 100,000 | $4.50 Strike: $4.50 | $450,000.00 |
DisclosureSEC source: 0001209191-23-003466 · doc4.xml · derivative · entry 1 Stark Charles William · CIK 0001901666 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest as to one-third of the option shares on the 12-month anniversary of the grant date and as to the remaining two-thirds of the option shares in 24 equal monthly installments as of the end of each month after such anniversary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.